Alto Neuroscience (ANRO) Projected to Post Earnings on Wednesday

Alto Neuroscience (NYSE:ANRO) is expected to be announcing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Alto Neuroscience to announce earnings of ($0.6735) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, analysts expect Alto Neuroscience to post ($2.69) EPS for the current fiscal year and ($2.92) EPS for the next fiscal year.

Alto Neuroscience Stock Up 2.2%

ANRO opened at $23.19 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The company has a market cap of $910.13 million, a price-to-earnings ratio of -9.60 and a beta of 1.42. Alto Neuroscience has a one year low of $10.62 and a one year high of $37.48. The business’s fifty day moving average is $27.77 and its two-hundred day moving average is $24.22.

Insider Activity

In other news, CFO Nicholas Smith sold 24,056 shares of the firm’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the transaction, the chief financial officer owned 24,060 shares of the company’s stock, valued at approximately $621,229.20. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 11.25% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on ANRO. HC Wainwright increased their price target on shares of Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Wedbush boosted their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. BTIG Research upped their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $37.88.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and central nervous system disorders. The company combines neuroscience research, clinical data and biomarker-based approaches to identify patients who may be more likely to respond to specific treatments.

Alto Neuroscience’s investigational pipeline includes therapies intended to address conditions such as major depressive disorder, bipolar depression, schizophrenia and associated cognitive impairment.